Puma Biotechnology Quarterly Balance Sheet
NASDAQ: PBYIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Puma Biotechnology financial position
As of Jun 30, 2026, Puma Biotechnology reported total assets of $192.7 million, down 1.1% from a year earlier against total liabilities of $54.2 million. Shareholders' equity stood at $138.5 million, or 71.9% of assets. The company held $36.5 million in cash and equivalents against $0 of debt, a net cash position of $36.5 million.
The current ratio (current assets divided by current liabilities) was 2.91, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
Puma Biotechnology balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 36.54M | 36.19M | 29.64M | 53.52M | 54.66M | 63.03M | 69.22M | 67.26M | 67.15M | 76.75M | 84.58M | 81.80M |
| Short-Term Investments | 57.37M | 65.35M | 67.89M | 40.86M | 41.36M | 30.14M | 31.75M | 29.46M | 29.68M | 30.41M | 11.35M | 3.23M |
| Receivables | 34.06M | 26.33M | 53.65M | 33.56M | 25.91M | 25.17M | 32.01M | 54.64M | 28.11M | 24.58M | 47.84M | 28.97M |
| Inventory | 13.32M | 8.69M | 5.51M | 9.48M | 8.59M | 8.75M | 8.72M | 2.67M | 9.05M | 7.10M | 7.08M | 5.68M |
| Total Current Assets | 145.07M | 142.26M | 162.69M | 143.58M | 136.58M | 132.51M | 147.66M | 156.82M | 137.72M | 143.03M | 156.19M | 125.35M |
| Property, Plant & Equipment | 103.00K | 124.00K | 187.00K | 305.00K | 388.00K | 474.00K | 515.00K | 601.00K | 680.00K | 757.00K | 855.00K | 907.00K |
| Intangible Assets | — | — | 41.39M | — | — | — | 51.13M | — | — | — | 60.87M | — |
| Total Assets | 192.74M | 192.70M | 216.30M | 202.86M | 194.92M | 196.18M | 213.33M | 220.72M | 205.00M | 214.15M | 230.53M | 203.60M |
| Accounts Payable | 3.10M | 8.17M | 5.06M | 6.39M | 5.42M | 6.03M | 5.51M | 7.51M | 13.50M | 8.96M | 6.89M | 5.06M |
| Short-Term Debt | 0 | 11.28M | 22.52M | 33.72M | 34.00M | 45.33M | 45.33M | 45.33M | 45.33M | 45.33M | 34.00M | 22.66M |
| Total Current Liabilities | 49.83M | 59.74M | 81.25M | 82.73M | 79.10M | 86.66M | 96.11M | 110.40M | 104.30M | 98.19M | 99.38M | 67.36M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 10.87M | 10.65M | 21.72M | 32.75M | 43.73M | 54.69M | 65.66M | 76.63M |
| Total Liabilities | 54.19M | 64.28M | 85.96M | 87.59M | 90.20M | 99.07M | 121.21M | 149.63M | 156.49M | 163.17M | 177.09M | 164.86M |
| Shareholders' Equity | 138.54M | 128.42M | 130.34M | 115.27M | 104.72M | 97.11M | 92.13M | 71.09M | 48.51M | 50.98M | 53.44M | 38.74M |
| Retained Earnings | -1.28B | -1.29B | -1.28B | -1.30B | -1.31B | -1.31B | -1.31B | -1.33B | -1.35B | -1.35B | -1.35B | -1.36B |
| Total Debt | 0 | 11.28M | 22.52M | 33.72M | 44.87M | 55.98M | 67.05M | 78.08M | 89.06M | 100.02M | 99.66M | 99.30M |
| Net Cash (Debt) | 93.90M | 90.26M | 75.00M | 60.67M | 51.16M | 37.19M | 33.92M | 18.65M | 7.77M | 7.14M | -3.72M | -14.27M |
| Shares Outstanding | 51.10M | 50.88M | 50.41M | 50.38M | 49.89M | 49.62M | 49.11M | 49.07M | 48.46M | 48.21M | 47.65M | 47.54M |
This table shows 12 quarterly periods of Puma Biotechnology's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow PBYI's reporting calendar. What is a balance sheet?